Role of Heme-oxygenase (HO) and Nitric Oxide (NO) Pathway in Patients With Obstructive Sleep Apnea (OSA) and Pulmonary Hypertension (PH)

Research design: This is a controled prospective study.

Methodology:

Patients with newly diagnosed and untreated OSA with total apnea-hypopnea index (AHI) >5/h, and control (AHI<5/h) will be recruited from the Long Beach VA sleep center. Controls are subjects without OSA or other sleep disorders and no sign of pulmonary hypertension based on echo. The investigators also measure pulmonary artery pressure by 2D Echo and exclude patient with any sign of left heart dysfunction. PH will be defined as RVSP > 35 mmHg or mean PA pressure>25 mmHg. The investigators will recruit subjects with and without PH and OSA in three separate groups:

1. group one : OSA+ PH,
2. group two: normal individual with no OSA and no PH,
3. group three: OSA with no PH Pulmonary function test will be done to exclude patients with underlying lung disease.

The inclusion criteria is: Age >20, AHI >5, AHI <5 (as control), RVSP > 35 mmHg OR Mean PA pressure>25 mmHg, RVSP < 35 mmHg OR Mean PA pressure < 25 mmHg (as control).

Subjects will be excluded if they had known peripheral vascular disease, liver disease, hemolytic anemia, inflammatory disease, active infection, or if they were pregnant, on therapy for OSA, on chronic steroid treatment, or younger than 20 years of age, patients with left heart failure (systolic or diastolic), patients are on PH medications including sildenafil, active smokers, COPD and asthma, active infection or inflammatory disease and collagen vascular disease.

Nocturnal polysomnography will be performed and scored according to the American Academy of Sleep Medicine.

Exhaled Carbon monoxide (CO) will be measured with a calibrated fuel cell type electrochemical device with sensor sensitivity of 1 ppm. The mean of three reproducible measurements will be recorded and corrected for ambient CO.

Exhaled Nitric Oxide (NO) will be measured. At each testing session, at least three flow-regulated FENO measurements will be performed.

The investigators will repeat 2D Echo and measurements of above factors after 3 months of CPAP treatment. The investigators also check patient's compliance with the treatment by downloading data off of their CPAP device.

Each subject will be informed of the experimental procedures, which is approved by the Human Investigation Committee of the VA-Long Beach.

Finding:

The investigators hypothesize that HO pathway causing perturbation of pulmonary endothelial function by inhibition of nitric oxide.

Clinical significance:

OSA is associated with PH, but exact mechanism is not well known. In the past, I have shown that increased endogenous CO in the setting of elevated NO concentration is associated with endothelial dysfunction in patient with OSA. Therefore, the investigators sought to investigate the roles of HO and NO pathways in patients with OSA associated with PH.

Impact/significance:

It addresses a fundamental gap in our understanding of how OSA results in increase the pulmonary artery pressure and if substantiated, will provide the basis for the design and testing of new approaches to prevention and treatment of OSA.

Study Overview

• Status: Unknown
• Conditions: Obstructive Sleep Apnea; Pulmonary Hypertension
• Intervention / Treatment: Other: measure exhaled carbon monoxide and nitric oxide

• Study Type: Observational
• Enrollment (Anticipated): 60

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with newly diagnosed and untreated OSA with total apnea-hypopnea index (AHI) >5/h, and control (AHI<5/h) will be recruited from the Long Beach VA sleep center. Controls are subjects without OSA or other sleep disorders and no sign of pulmonary hypertension based on echo. We also measure pulmonary artery pressure by 2D Echo and exclude patient with any sign of left heart dysfunction. PH will be defined as RVSP > 35 mmHg or mean PA pressure>25 mmHg. We will recruit subjects with and without PH and OSA in three separate groups:

1. group one : OSA+ PH,
2. group two: normal individual with no OSA and no PH,
3. group three: OSA with no PH Pulmonary function test will be done to exclude patients with underlying lung disease.

Description

Inclusion Criteria:

1. participants must satisfy diagnostic criteria for Obstructive sleep apnea.
2. evidence of pulmonary hypertension disease base upon one or more of the following: RVSP > 35 mmHg OR Mean PA pressure>25 mmHg, RVSP < 35 mmHg OR Mean PA pressure < 25 mmHg (as control).
3. age greater than or equal to 20 years.
4. no significant alcohol use (7 or fewer drinks per week).

Exclusion Criteria:

1. peripheral vascular disease
2. liver disease
3. Pregnancy. A serum pregnancy test must be performed and negative in all women of child bearing potential within 2 weeks prior to enrollment.
4. Any medical or psychosocial condition that, in the opinion of the investigator, could jeopardize the subject's participation, and compliance with the study criteria.
5. hemolytic anemia
6. inflammatory disease
7. active infection,
8. on therapy for OSA,
9. on chronic steroid treatment,
10. younger than 20 years of age,
11. patients with left heart failure (systolic or diastolic),
12. patients are on pulmonary hypertension medications including sildenafil,
13. active smokers,
14. COPD and asthma,
15. active infection or inflammatory disease
16. collagen vascular disease.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Prospective

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Obstructive sleep apnea with pulmonary hypertension; Patients with AHI> 5/h and pulmonary hypertension with RVSP>35 mmHg on Echo	Other: measure exhaled carbon monoxide and nitric oxide
control; patients with AHI<5/h and RVSP<35 mmHg on Echo	Other: measure exhaled carbon monoxide and nitric oxide
OSA with no Pulmonary hypertension; patients with AHI>5/h, but RVSP<35 mmHg on Echo	Other: measure exhaled carbon monoxide and nitric oxide

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
exhaled carbon monxide and nitric oxide	The concentration of both gas will be measured in PPM and will be repeated in 3 month after CPAP is being used.	3 month
RVSP as sorrogate of Pulmonary artery pressure	It will be measured by 2D-Echo in mmHg and correlation of RVSP and above two gases will be assessed.	3 month

Collaborators and Investigators

• Sponsor: Southern California Institute for Research and Education

Study record dates

Study Major Dates

• Study Start: March 1, 2015
• Primary Completion (Anticipated): March 1, 2016
• Study Completion: December 7, 2022

Study Registration Dates

• First Submitted: February 9, 2015
• First Submitted That Met QC Criteria: February 12, 2015
• First Posted (Estimate): February 20, 2015

Study Record Updates

• Last Update Posted (Estimate): February 20, 2015
• Last Update Submitted That Met QC Criteria: February 12, 2015
• Last Verified: February 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Nervous System Diseases; Respiratory Tract Diseases; Apnea; Respiration Disorders; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Lung Diseases; Sleep Apnea Syndromes; Sleep Apnea, Obstructive; Hypertension; Hypertension, Pulmonary; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Vasodilator Agents; Autonomic Agents; Peripheral Nervous System Agents; Antimetabolites; Protective Agents; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Antioxidants; Free Radical Scavengers; Endothelium-Dependent Relaxing Factors; Gasotransmitters; Nitric Oxide; Carbon Monoxide
• Other Study ID Numbers: OSA-PH-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No